Stockscreener 앱 받기
71.53
0.10%
-0.07
시장 영업 전:
72.41
0.88
+1.23%
전일 마감가:
$71.60
열려 있는:
$71.725
하루 거래량:
1.14M
Relative Volume:
0.70
시가총액:
$8.48B
수익:
$1.40B
순이익/손실:
$316.89M
주가수익비율:
28.71
EPS:
2.4918
순현금흐름:
$644.59M
1주 성능:
+7.50%
1개월 성능:
+8.59%
6개월 성능:
+12.95%
1년 성능:
+33.58%
1일 변동 폭
$70.71
$72.25
1주일 범위
$65.59
$72.25
52주 변동 폭
$51.06
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
71.53 | 8.49B | 1.40B | 316.89M | 644.59M | 2.4918 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Quick ratio of Halozyme Therapeutics, Inc. – XETR:RV7 - TradingView
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics, Inc. Income Statement – XETR:RV7 - TradingView
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Halozyme Therapeutics(HALO.US) Officer Sells US$3.37 Million in Common Stock - Moomoo
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options By Investing.com - Investing.com South Africa
Halozyme Therapeutics Stock Gains 5.2% on Analyst Buy Rating and argenx Data NewsNews and Statistics - IndexBox
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options - Investing.com
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today - Yahoo Finance
Halozyme (NASDAQ: HALO) CEO sells 50K shares after exercising 50K options - Stock Titan
Halozyme Therapeutics Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Benchmark reiterates Halozyme stock Buy rating on long-term potential - Investing.com
Benchmark reiterates Halozyme stock Buy rating on long-term potential By Investing.com - Investing.com Canada
Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E - ChartMill
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
Insider Sell Alert: Bernadette Connaughton Sells Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus
Director at Halozyme (NASDAQ: HALO) sells shares under Rule 10b5-1 plan - Stock Titan
HALO Stock Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 26% Potential Upside for Investors - DirectorsTalk Interviews
Halozyme earnings up next: Can drug delivery platform sustain growth? By Investing.com - Investing.com Nigeria
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme to acquire Elektrofi, a biopharma focused on drug delivery - MSN
Halozyme Therapeutics Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Implied volatility surging for Halozyme Therapeutics stock options - MSN
Halozyme Therapeutics Q1 earnings call highlights - MSN
Implied Volatility Surging for Halozyme Therapeutics Stock Options - Yahoo Finance
Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a Promising 22.8% Potential Upside - DirectorsTalk Interviews
(HALO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
HALO News | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Flat Share Price And Strong Longer Term Returns - Sahm
New GSK ENHANZE Deal and Bigger Buybacks Might Change The Case For Investing In Halozyme (HALO) - simplywall.st
Halozyme posts strong Q1 earnings, boosts share buyback with $1B program amid robust royalty growth - Pluang
Halozyme Therapeutics: Royalty King (NASDAQ:HALO) - Seeking Alpha
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Alteogen Gains Momentum in Patent Defense for Merck's Subcutaneous Keytruda - thelec.net
Halozyme Therapeutics (HALO) Stock Analysis: A 27.3% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up - MSN
Halozyme Therapeutics Experiences Valuation Adjustment Amid Competitive Biotechnology Landscape - Markets Mojo
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Halozyme Therapeutics Q1 2026 Earnings Review | HALO StockNews and Statistics - IndexBox
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO) - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook - Yahoo Finance
Morgan Stanley Smith Barney files Form 144 (NASDAQ: HALO) to sell 14,700 shares - Stock Titan
A Look At Halozyme Therapeutics (HALO) Valuation After Q1 Growth, GSK ENHANZE Deal And US$1b Buyback - Sahm
Arbejdsmarkedets Tillaegspension Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback - MSN
Halozyme appoints Darren Snellgrove as CFO - MSN
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Jun 02 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Jun 03 '26 |
Option Exercise |
12.07 |
10,000 |
120,700 |
777,780 |
| Torley Helen | PRESIDENT AND CEO |
Jun 01 '26 |
Sale |
67.58 |
20,000 |
1,351,610 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Jun 02 '26 |
Sale |
66.39 |
20,000 |
1,327,745 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Jun 03 '26 |
Sale |
69.07 |
10,000 |
690,653 |
767,780 |
| Connaughton Bernadette | Director |
Jun 01 '26 |
Sale |
66.21 |
1,625 |
107,591 |
43,669 |
1.13%
3.22%
자본화:
|
볼륨(24시간):